Guardant Health and Quest Diagnostics previously announced a multi-year collaboration to offer the FDA-approved Shield blood-based colorectal cancer screening test to Quest's large U.S. provider ...
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States Collaboration to enable streamlined and ...
Guardant Health is emerging as a leader in precision oncology, driven by innovation in blood-based cancer detection and strong revenue growth. Recent FDA approvals and partnerships, including with ...
SALT LAKE CITY, July 10, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on June 1, 2020 by OMNIQ, Inc. (OTCQB:OMQS), please be advised that the second paragraph as originally ...
Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network Shield is the first and only blood test to receive full ...
PALO ALTO, Calif. & SECAUCUS, N.J., September 24, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback